What Viberzi treats: main uses and benefits

Viberzi (eluxadoline) is generally applied in addressing the core symptoms linked to Irritable Bowel Syndrome with Diarrhea (IBS-D) in adults. It is considered relevant in conditions characterized by periods of heightened symptoms, which involve symptoms related to physical discomfort (abdominal pain) and frequent loose stools. Its therapeutic use is relevant in contexts marked by increased discomfort and tension.

It is applied across therapeutic domains where additional symptomatic support is needed, primarily helping to ease diarrhea and abdominal pain. This may assist with maintaining functional stability during episodes of heightened symptoms, which are often used during phases when symptoms become more noticeable.

“Supportive relief helps with managing symptom fluctuations more steadily.”

The medication is commonly used across conditions presenting with acute episodes where short-term symptomatic assistance is needed.

Quick Fact: Supportive management for symptoms related to physical discomfort and systemic imbalance

Who can and cannot use Viberzi?

Viberzi (eluxadoline) is officially restricted to adult patients (18 years of age and older) for the treatment of Irritable Bowel Syndrome with Diarrhea (IBS-D). Eligibility is strictly governed by medical history and organ function status, as defined in regulatory labeling.

Absolute Contraindications (Must Not Use)

Use of eluxadoline is prohibited for patients with specific health conditions, including:

• Patients who have had their gallbladder removed (post-cholecystectomy).
• Severe hepatic impairment (Child-Pugh Class C).
• History of pancreatitis or biliary/pancreatic duct obstruction.
• Chronic or severe constipation or known gastrointestinal obstruction.
• Alcohol abuse or consumption exceeding three alcoholic beverages per day.

Conditional Eligibility and Restrictions

Official labeling defines conditional use for populations requiring dosage adjustment. Use is permitted, but requires a lower strength, for those with mild or moderate hepatic impairment or moderate or severe renal impairment. The safety and efficacy of Viberzi are not established for use in pediatric patients, pregnant women, or breastfeeding mothers.

The official regulatory documentation for Viberzi establishes restrictions based on both pharmacokinetic (PK) and pharmacodynamic (PD) interaction patterns.

Formal Contraindications and Restrictions

Co-administration with potent OATP1B1 inhibitors, such as Cyclosporine, is contraindicated due to the risk of a significant increase in eluxadoline plasma exposure. The medicine is also contraindicated in patients with severe hepatic impairment (Child-Pugh Class C) because clearance impairment results in significantly increased plasma concentrations (up to 16-fold). A further substance-specific contraindication applies to individuals who consume more than three alcoholic beverages per day, which is formally linked to an increased risk of acute pancreatitis.

Exposure and Pharmacodynamic Interactions

Eluxadoline is a substrate of the OATP1B1 transporter and an inhibitor of both OATP1B1 and BCRP. This transporter-mediated profile dictates that co-administration with less potent OATP1B1 inhibitors (e.g., Gemfibrozil) requires a mandatory dose reduction to 75 mg twice daily as a regulatory measure to limit increased exposure. As an inhibitor, eluxadoline may also increase the systemic exposure of co-administered substrates, including certain statins (e.g., Rosuvastatin). Furthermore, use with other drugs that may cause constipation, such as Opioids or Anticholinergics, should be avoided due to a pharmacodynamic additive effect that increases the risk of severe constipation. Patients with mild or moderate hepatic impairment (Child-Pugh Class A or B) also require this mandatory dose reduction.

The mechanism of Viberzi (eluxadoline) is defined by its highly targeted action on opioid receptors located almost exclusively within the Enteric Nervous System (ENS) of the gut. By confining its activity to the periphery, the molecule modulates GI function with minimal engagement of the central nervous system.

Modulating Propulsion and Fluid Control

Eluxadoline works by acting as an agonist (activator) at the mu-opioid and kappa-opioid receptors. This action initiates an inhibitory signaling sequence in nerve cells that control the speed and force of muscle contractions in the colon, while also reducing the release of fluid and electrolytes into the intestinal lumen. This process leads to slower intestinal transit and decreased fluid volume, resulting in a specific alteration of GI function.

Modulation of Peripheral Visceral Sensation

Strategic Receptor Balance (Mixed Modulation)

The molecule also engages the opioid receptors found on peripheral sensory neurons (afferent neurons) within the gut wall. By adjusting the excitability of these nerves, the mechanism reduces the transmission of excessive sensory signals. This modulation modifies the intensity of signals transmitted by peripheral sensory neurons.

Additionally, Viberzi's mechanism utilizes a mixed modulation strategy: it combines the mu-opioid agonism with simultaneous delta-opioid receptor antagonism (blocking). The delta-antagonism counteracts some of the inherent mechanistic effects of strong mu-activation, namely the potential for severely restricted motility. This balancing effect modulates the resulting reduction in GI movement.

The administration of Viberzi (eluxadoline) is restricted to the oral route using the available 75 mg and 100 mg tablets for adults.

Dosing and Administration

The standard adult dosing schedule is 100 mg twice daily (BID), taken with food in the morning and evening. The medicine is not intended for dose titration and is started at the prescribed therapeutic dose.

However, a reduced dose of 75 mg twice daily is specified for several distinct clinical scenarios:

• Patients who are unable to tolerate the standard 100 mg dose.
• Patients with mild or moderate hepatic impairment (Child-Pugh A or B).
• Patients receiving concomitant OATP1B1 inhibitors.
• Patients with moderate or severe renal impairment or End-Stage Renal Disease (ESRD) not yet on dialysis.

Administration occurs with food for both the 75 mg and 100 mg doses. If a dose is missed, the standard approach is to skip the missed dose and resume the normal dosing schedule at the next designated time; two doses are never taken at once to compensate for a skipped dose.

Treatment is intended for continuous daily use as directed, and the medicine is discontinued if the patient develops severe constipation that persists for more than four days.

Research Evidence / Overview of Studies for Viberzi (Eluxadoline)

Evidence for Use in Irritable Bowel Syndrome with Diarrhea (IBS-D)

The clinical evaluation of Viberzi (eluxadoline) for Irritable Bowel Syndrome with Diarrhea (IBS-D) was primarily conducted through large-scale, randomized, double-blind, placebo-controlled clinical trials. These studies are considered high-quality evidence and contribute to the evidence used for regulatory review. Researchers focused on adult patients (age 18 and older) who met the standard criteria for IBS-D.

The main objective of this research was to examine changes, if any, that occurred simultaneously in two specific IBS-D symptoms: abdominal pain and stool consistency. Studies defined a "composite response" as an improvement in both pain and a return to a more normal stool form. Research explored how symptoms evolved in the observed populations compared to those taking a placebo. Findings describe patterns observed in the studies related to this composite measure over the short-term (12 weeks) and intermediate-term (26 weeks) observation periods.

Long-Term Evidence and Durability of Study Outcomes

This section outlines the duration for which patient outcomes were studied in the primary research. The key outcome assessments, which describe changes in symptoms, were measured over intervals of up to six months (26 weeks). While these intermediate-term studies report how symptoms evolved in the observed populations up to 26 weeks, one of the pivotal trials did continue to monitor patients for safety for a longer period, up to 52 weeks. Research highlights changes measured during the study period, but long-term outcomes regarding the persistence of these patterns over multiple years are not fully established in the published clinical trial evidence.

What Remains Uncertain About the Research

Official regulatory documents and peer-reviewed analyses clarify areas where data are still emerging or where evidence is limited. A key research limitation is the duration of outcome follow-up, as the primary evidence relies on outcomes observed over 6 months or less. Data for certain groups remain insufficient, particularly for pediatric patients. Additionally, the majority of patients enrolled in the main trials were White, which means the relevance of the findings to other ethnic or racial groups is less characterized. Comparative evidence is also lacking; there are no definitive head-to-head trials to assess the clinical outcomes of eluxadoline against other pharmacological agents studied for IBS-D.

Key Studies & References

1. MedlinePlus: Eluxadoline

Common questions about Viberzi (FAQ)

Q: What is the active ingredient in Viberzi and how does it work?

The active ingredient in Viberzi is eluxadoline. According to official product information, it works by acting on specific opioid receptors located almost exclusively within the gut. This action is formally defined as being designed to help manage the symptoms of Irritable Bowel Syndrome with Diarrhea (IBS-D) by reducing muscle contractions and fluid secretion.

Q: What is the primary condition Viberzi is used to treat?

Regulatory documents state that Viberzi is officially indicated only for adults with Irritable Bowel Syndrome with Diarrhea (IBS-D). Its purpose is to help improve specific symptoms of this condition, such as abdominal pain and diarrhea, as observed in clinical trials.

Q: How long does it usually take for Viberzi to start working?

Clinical reports indicate that drug action may begin early, with some patients noting initial changes within the first week of treatment. However, the full benefits, such as sustained symptom relief, were observed in studies over periods of weeks or months of consistent administration.

Q: Is Viberzi a narcotic or a controlled substance?

Viberzi contains the active ingredient eluxadoline, which is classified as a Schedule IV controlled substance by the U.S. Drug Enforcement Administration (DEA). This classification is based on regulatory assessment of its potential for abuse and psychological dependence. The official product information includes specific precautions regarding its controlled status.

Q: What should be done if a dose of Viberzi is missed?

Official regulatory instructions state that if a dose is missed, the dose should be skipped, and the patient should resume the normal dosing schedule at the next designated time. Regulatory documents advise against taking two doses at once to compensate for the skipped dose.

Q: What is the risk of pancreatitis associated with Viberzi?

Official product labeling highlights the risk of serious pancreatitis (inflammation of the pancreas), especially for patients without a gallbladder (post-cholecystectomy). The official information details specific contraindications and restrictions for use, and notes that symptoms like severe abdominal pain may indicate this condition.

Viberzi (eluxadoline) must be stored at a Controlled Room Temperature, consistent with official regulatory labeling for product stability.

Storage Conditions

• Temperature: Store the tablets between 20 C to 25 C (68 F to 77 F), with permitted short-term excursions up to 30 C (86 F). The medicine must be kept from freezing and away from excessive heat.
• Protection: Keep the medication in the container it came in, ensure the container is tightly closed, and protect it from both moisture and direct light.
• Child Safety/Security: As a Schedule IV controlled substance, the product must be kept in a safe place to protect it from theft and must be stored out of the reach of children and pets.

Disposal Instructions

Do not flush unused or expired Viberzi down a drain. The official procedure is to use a drug take-back program (e.g., at pharmacies or police stations) whenever possible. If a take-back option is unavailable, the product should be mixed with an undesirable substance (such as dirt or used coffee grounds) and placed in a sealed container before discarding in household trash.